DBI and metabolic syndrome: Conversely, experimental settings of autophagy induction, for example, by ATG5 (Pyo et al, 2013) or TFEB overexpression (Settembre et al, 2013), or genetic or antibody‐mediated neutralization of DBI/ACBP (Bravo‐San Pedro et al, 2019), are sufficient to alleviate the metabolic anomalies tied to systemic energetic dysregulation and to mitigate characteristic signs of metabolic syndromes.